

ASX Announcement

Melbourne, Australia, 25 November 2022

Exopharm to Receive \$0.96 million in Prepayment of R&D Tax Incentive Claim

Highlights:

- **Prepayment of \$961,000 for the Research and Development (R&D) tax incentive for FY 2022-2023**
- **equivalent to 80% of its accrued R&D tax incentive for the period 1 July 2022 – 30 October 2022**
- **repayment timed to coincide with the receipt of the Company's FY 2023 R&D tax incentive refund, expected by 30 November 2023**

Genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX:EX1) is pleased to advise that it has entered into a non-dilutive cash loan agreement with Radium Capital (Radium), providing early access to a significant part of the Research and Development (R&D) tax incentive for FY 2022-2023.

The previous loan agreement relating to announcements on 16 June 2022, 28 July 2022 and 27 October 2022 for FY 2021-2022 has been concluded and fully repaid.

The Radium cash facility provides Exopharm with immediate funds equivalent to 80% of its accrued R&D tax incentive for the period 1 July 2022 – 30 October 2022. The cash advance of \$961,000 was based on eligible R&D tax incentive expenditure that has been verified by an independent accounting firm.

Dr Ian Dixon, CEO & Managing Director of Exopharm said "The ongoing use of these facilities, first utilised for FY 2021-2022, provides the Company with additional runway. This standard loan facility provides us a significant non-dilutive cash injection. These types of facilities are a common feature of the biotechnology scene in Australia."

The advance from the Radium facility is expected in the next week, with the facility accruing interest at the compounded rate of 1.17% per month, and repayment timed to coincide with the receipt of the Company's FY 2023 R&D tax incentive refund, expected by 30 November 2023.

By the Managing Director - this announcement has been authorised for release by the Managing Director.

COMPANY AND MEDIA ENQUIRIES:

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

www.exopharm.com

P: +61 (0)3 9111 0026

Ian Dixon

Managing Director

Tel: +61 418 561 907

ian.dixon@exopharm.com

ABOUT EXOPHARM

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.

Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – **LEAP** manufacturing technology, **LOAD** API loading technologies and **EVPS** tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

In addition, Exopharm is using its technology platform to enable its own product development programs - each aimed at delivering a transformative medicine for an unmet medical need.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.